Short Interest in Oculis Holding AG (NASDAQ:OCS) Expands By 212.7%

Oculis Holding AG (NASDAQ:OCS) was the target of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 316,332 shares, a growth of 212.7% from the December 15th total of 101,167 shares. Based on an average trading volume of 114,783 shares, the days-to-cover ratio is presently 2.8 days. Approximately 0.6% of the company’s shares are sold short. Approximately 0.6% of the company’s shares are sold short. Based on an average trading volume of 114,783 shares, the days-to-cover ratio is presently 2.8 days.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on OCS. Chardan Capital reissued a “buy” rating and set a $51.00 price target on shares of Oculis in a research report on Tuesday, November 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Oculis in a report on Wednesday, October 8th. Stifel Nicolaus boosted their target price on Oculis from $35.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, December 19th. JPMorgan Chase & Co. started coverage on Oculis in a research report on Friday, December 19th. They set an “overweight” rating and a $38.00 price target on the stock. Finally, Lifesci Capital began coverage on Oculis in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective for the company. Eight research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Syquant Capital Sas bought a new stake in shares of Oculis in the 4th quarter valued at about $3,849,000. Woodline Partners LP lifted its position in shares of Oculis by 65.8% in the third quarter. Woodline Partners LP now owns 83,833 shares of the company’s stock valued at $1,474,000 after buying an additional 33,265 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Oculis during the 2nd quarter worth approximately $393,000. Bosun Asset Management LLC acquired a new position in shares of Oculis during the 2nd quarter worth approximately $378,000. Finally, Compagnie Lombard Odier SCmA raised its stake in Oculis by 11.5% in the 2nd quarter. Compagnie Lombard Odier SCmA now owns 97,000 shares of the company’s stock valued at $1,883,000 after acquiring an additional 10,000 shares during the period. Institutional investors own 22.30% of the company’s stock.

Oculis Price Performance

Shares of NASDAQ:OCS traded up $0.62 during midday trading on Wednesday, reaching $23.66. The company had a trading volume of 217,059 shares, compared to its average volume of 148,537. Oculis has a 1-year low of $14.00 and a 1-year high of $24.50. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The business’s 50 day moving average price is $20.15 and its 200 day moving average price is $19.05.

Oculis (NASDAQ:OCS) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.10. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%.The firm had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.23 million. On average, equities research analysts predict that Oculis will post -2.09 EPS for the current year.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.